Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells.

Ziegler CG, Ullrich M, Schally AV, Bergmann R, Pietzsch J, Gebauer L, Gondek K, Qin N, Pacak K, Ehrhart-Bornstein M, Eisenhofer G, Bornstein SR.

Mol Cell Endocrinol. 2013 May 22;371(1-2):189-94. doi: 10.1016/j.mce.2012.12.011. Epub 2012 Dec 23.

2.

Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.

Ziegler CG, Brown JW, Schally AV, Erler A, Gebauer L, Treszl A, Young L, Fishman LM, Engel JB, Willenberg HS, Petersenn S, Eisenhofer G, Ehrhart-Bornstein M, Bornstein SR.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15879-84. doi: 10.1073/pnas.0907843106. Epub 2009 Aug 27.

3.

Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.

Szepeshazi K, Schally AV, Treszl A, Seitz S, Halmos G.

Anticancer Drugs. 2008 Apr;19(4):349-58. doi: 10.1097/CAD.0b013e3282f9adce.

PMID:
18454045
4.

Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.

Kidd M, Schally AV, Pfragner R, Malfertheiner MV, Modlin IM.

Cancer. 2008 Mar 15;112(6):1404-14. doi: 10.1002/cncr.23303.

5.

The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.

Pozsgai E, Schally AV, Hocsak E, Zarandi M, Rick F, Bellyei S.

Int J Oncol. 2011 Oct;39(4):1025-32. doi: 10.3892/ijo.2011.1098. Epub 2011 Jun 23.

PMID:
21701777
6.

Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.

Zhao L, Yano T, Osuga Y, Nakagawa S, Oishi H, Wada-Hiraike O, Tang X, Yano N, Kugu K, Schally AV, Taketani Y.

Int J Oncol. 2008 Mar;32(3):593-601.

PMID:
18292936
7.

Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2.

Catanuto P, Tashiro J, Rick FG, Sanchez P, Solorzano CC, Glassberg MK, Block NL, Lew JI, Elliot SJ, Schally AV.

Horm Cancer. 2015 Jun;6(2-3):100-6. doi: 10.1007/s12672-015-0217-2. Epub 2015 Mar 10.

PMID:
25752763
8.

Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.

Szalontay L, Schally AV, Popovics P, Vidaurre I, Krishan A, Zarandi M, Cai RZ, Klukovits A, Block NL, Rick FG.

Cell Cycle. 2014;13(17):2790-7. doi: 10.4161/15384101.2015.945879.

9.

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.

Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG.

Oncotarget. 2012 Sep;3(9):988-97.

10.

The effect of GHRH antagonists on human glioblastomas and their mechanism of action.

Pozsgai E, Schally AV, Zarandi M, Varga JL, Vidaurre I, Bellyei S.

Int J Cancer. 2010 Nov 15;127(10):2313-22. doi: 10.1002/ijc.25259.

11.

Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.

Stangelberger A, Schally AV, Nagy A, Szepeshazi K, Kanashiro CA, Halmos G.

Prostate. 2006 Feb 1;66(2):200-10.

PMID:
16173040
12.

Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.

Rick FG, Schally AV, Block NL, Abi-Chaker A, Krishan A, Szalontay L.

Prostate. 2013 Jun;73(8):873-83. doi: 10.1002/pros.22633. Epub 2012 Dec 31.

PMID:
23280565
15.

Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI).

Kanashiro-Takeuchi RM, Takeuchi LM, Rick FG, Dulce R, Treuer AV, Florea V, Rodrigues CO, Paulino EC, Hatzistergos KE, Selem SM, Gonzalez DR, Block NL, Schally AV, Hare JM.

Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):559-63. doi: 10.1073/pnas.1119203109. Epub 2011 Dec 27.

16.

Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.

Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay L, Zarandi M, Ortmann O, Engel JB, Buchholz S.

Oncol Rep. 2013 Jul;30(1):413-8. doi: 10.3892/or.2013.2435. Epub 2013 Apr 29.

PMID:
23624870
17.

Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.

Guo J, Schally AV, Zarandi M, Varga J, Leung PC.

Reprod Biol Endocrinol. 2010 May 28;8:54. doi: 10.1186/1477-7827-8-54.

18.

Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.

Kovacs M, Zarándi M, Halmos G, Groot K, Schally AV.

Endocrinology. 1996 Dec;137(12):5364-9.

PMID:
8940358
19.

The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.

Stangelberger A, Schally AV, Zarandi M, Heinrich E, Groot K, Havt A, Kanashiro CA, Varga JL, Halmos G.

Prostate. 2007 Sep 1;67(12):1339-53.

PMID:
17624923
20.

Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.

Nagy A, Schally AV.

Biol Reprod. 2005 Nov;73(5):851-9. Epub 2005 Jul 20. Review.

PMID:
16033997

Supplemental Content

Support Center